Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis.
The interaction between cancer and its local microenvironment can determine properties of growth and metastasis. A critical component of the tumor microenvironment in this context is the cancer-associated fibroblast (CAF), which can promote tumor growth, angiogenesis and metastasis. It has been hypothesized that CAF may be derived from mesenchymal stromal cells (MSC), derived from local or distant sources. However, the signaling mechanisms by which tumors and MSCs interact to promote CAF-dependent cancer growth are largely unknown. In this study with in vitro and in vivo models using MDA-MB231 human breast cancer cells, we demonstrate that tumor-derived osteopontin (OPN) induces MSC production of CCL5; the mechanism involves OPN binding to integrin cell surface receptors and activator protein-1 c-jun homodimer transactivation. In a murine xenograft model, concomitant inoculation of MSC with MDA-MB231 cells induces: (i) significantly increased growth and metastasis of MB231 cells and (ii) increased MSC migration to metastatic sites in lung and liver; this mechanism is both OPN and CCL5 dependent. MSCs retrieved from sites of metastases exhibit OPN-dependent expression of the CAF markers, α-smooth muscle actin, tenascin-c, CXCL12 (or stromal cell-derived factor 1) and fibroblast-specific protein-1 and the matrix metalloproteinases (MMP)-2 and MMP-9. Based upon these results, we propose that tumor-derived OPN promotes tumor progression via the transformation of MSC into CAF.
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Zhiyong
Z
Mi
Syamal D
SD
Bhattacharya
Victoria M
VM
Kim
Hongtao
H
Guo
Lindsay J
LJ
Talbot
Paul C
PC
Kuo
D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D018946:Chemokine CCL5 / Q000502:physiology*; D018920:Coculture Techniques; D005260:Female; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D051379:Mice; D016513:Mice, SCID; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D053495:Osteopontin / Q000502:physiology*; D017154:Stromal Cells / Q000502:physiology*; D014183:Transplantation, Heterologous
C483024:CCL5 protein, human; D018946:Chemokine CCL5; D053495:Osteopontin
Annu Rev Pharmacol Toxicol. 2001;41:723-49
11264474
Cell. 2008 Jun 13;133(6):994-1005
18555776
Stem Cells. 2009 Jul;27(7):1548-58
19544460
Cancer Res. 2008 Jun 1;68(11):4331-9
18519693
Carcinogenesis. 2009 Apr;30(4):589-97
19181699
Curr Opin Genet Dev. 2009 Feb;19(1):67-73
19211240
Proc Assoc Am Physicians. 1997 Jan;109(1):1-9
9010911
J Immunol. 1993 Sep 1;151(5):2601-12
7689610
Mol Ther. 2009 Jan;17(1):153-61
18985031
Pathol Int. 2002 Jan;52(1):19-24
11940202
Am J Pathol. 1994 Sep;145(3):610-23
8080043
Cancer Lett. 2009 Oct 18;284(1):80-5
19427114
J Biol Regul Homeost Agents. 2002 Jul-Sep;16(3):190-5
12456016
Semin Cell Dev Biol. 2010 Feb;21(1):19-25
19857592
Int J Radiat Oncol Biol Phys. 1990 May;18(5):1061-7
2347715
Nat Med. 2008 May;14(5):518-27
18438415
Clin Cancer Res. 2001 Dec;7(12):4060-6
11751502
J Biol Chem. 2003 Aug 1;278(31):28593-606
12771144
J Natl Cancer Inst. 2002 Apr 3;94(7):513-21
11929952
Cancer Res. 2002 Feb 15;62(4):1093-102
11861388
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3337-43
16740755
Ann N Y Acad Sci. 1995 Apr 21;760:127-42
7540371
FASEB J. 2006 Jan;20(1):95-102
16394272
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90
14734468
Nature. 2007 Oct 4;449(7162):557-63
17914389
Clin Cancer Res. 2001 Oct;7(10):3097-105
11595701
Cancer Metastasis Rev. 2008 Mar;27(1):103-18
18049863
J Surg Res. 2004 Oct;121(2):228-41
15501463
PLoS One. 2009;4(4):e4992
19352430
J Cell Biochem. 1994 Sep;56(1):48-51
7528752